Interventional Oncology Devices – Market Insights – Asia Pacific

The Asia Pacific interventional oncology device market will see strong growth through 2032 driven by a large and rapidly expanding patient population, increasing popularity of minimally invasive surgeries, improving access to treatment, and growing physician acceptance of interventional oncology procedures. However, a lack of reimbursement, mixed results from clinical trials, and ongoing cost constraints in the region will remain a challenge for this market.

This Medtech 360 Report provides comprehensive data and analysis on the state of the market for interventional oncology devices in the Asia Pacific region from 2019 to 2032.

Overcoming the short-term consequences that COVID-19 pandemic has had on the interventional oncology devices, the market has begun to see a recovery toward prepandemic levels.

To what extent did COVID-19 affect the different procedure types in the interventional oncology device market?

How will procedure volume recover over the forecast period?

Physicians in the Asia Pacific region are looking for various minimally invasive interventional oncology devices to treat liver, kidney, and lung cancers.

What is the major demographic, economic, and local trend differences across the Asia Pacific region that impact the adoption of and demand for these devices?

What is the current competitive situation of the market, and how will it change during the forecast period?

What are the strategies employed by key competitors to position themselves in this market, and what challenges do they face?

What technologies are available, and which products are set to be launched in the different countries going forward?

Which major clinical trials are being conducted, and how will they impact the interventional oncology device market?

Reimbursement will be an important factor in the adoption of interventional oncology procedures in cost-conscious Asia Pacific region.

What is the reimbursement scenario in the Asia Pacific region?

How proper reimbursement availability will impact the interventional oncology device market in future?

 Ablation therapy procedures will continue to grow for the liver, kidney, and lung cancer indications. The adoption trends for different ablation modalities have changed in recent years. 

How will the market growth vary across different ablation device categories?

What factors are driving the uptake of each of the ablation device categories across the Asia Pacific market?

How does the uptake of microwave ablation devices affect other types of ablation devices, like RF ablation devices, and how are competitors preparing for this shift?

Increasing adoption of newer embolization technologies will lead to robust growth in the Asia Pacific embolization device market.

How will the market growth vary across different embolization device categories?

How does the current adoption scenario look like for different embolization device categories, and what factors will drive further penetration of these technologies over the forecast period?

What will be the impact of clinical guidance on the adoption of newer technologies in the embolization device market?

How will be the adoption of DEBs and radioembolization spheres affected by recent clinical trials?